世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

胃がん診断の世界市場:製品タイプ別(試薬・消耗品、機器)、疾患タイプ別(腺がん、胃リンパ腫、その他)、エンドユーザー別(病院、腫瘍専門クリニック、診断ラボ、がん研究機関、その他)、地域別(COVID-19の影響による規模・動向、2028年までの予測)分析


Global Gastric Cancer Diagnostic Market: Analysis By Product Type (Reagents and Consumables and Instruments), By Disease Type (Adenocarcinoma, Gastric Lymphoma and Others), By End User (Hospitals, Oncology Specialty Clinics, Diagnostic Labs, Cancer Research Institutes And Others), By Region Size and Trends with Impact of COVID-19 and Forecast up to 2028

胃がん診断には、臨床評価、内視鏡検査やCTスキャンなどの画像検査、組織検査のための生検、特定のマーカーを検出するための血液検査などを通じて胃がんを特定する包括的なプロセスが含まれる。胃がん診断の成長... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Daedal Research
デダルリサーチ
2024年1月10日 US$2,250
シングルユーザライセンス(印刷不可)
ライセンス・価格情報
注文方法はこちら
143 英語

 

サマリー

胃がん診断には、臨床評価、内視鏡検査やCTスキャンなどの画像検査、組織検査のための生検、特定のマーカーを検出するための血液検査などを通じて胃がんを特定する包括的なプロセスが含まれる。胃がん診断の成長を促す主な目的のひとつは、早期発見に重点を置くことである。早期発見によってタイムリーな介入と治療が可能になり、予後と治療成績が大幅に改善する。2022年の世界の胃がん診断市場は14.6億米ドルで、2028年には22.5億米ドルに達する見込みである。

胃がん診断薬の需要増加を促進する顕著な要因の1つは、世界的な胃がん罹患率の上昇と胃がん予防に関する人々の意識の高まりである。特にリスクの高い人々の間で、予防医療や定期的な検診が重視されるようになっていることが、市場拡大の原動力となっている。さらに、政府の支援策、医療インフラの整備、研究開発活動の急増は、診断手順を合理化し、全体的な効率を向上させることで市場の成長に寄与している。さらに、胃がん診断市場は、高齢者人口が増加し、リキッドバイオプシーなどの革新技術、画像診断技術や分子診断の改良、AIと医療の融合などが普及するにつれて成長すると予測される。世界の胃がん診断市場価値は、2023-2028年の予測期間中にCAGR 7.46%で成長すると予測される。

市場細分化分析:

製品タイプ別:報告書によると、世界の胃がん診断市場は、製品タイプに基づいて2つのセグメントに区分される:試薬・消耗品と機器である。試薬・消耗品は胃がん診断のルーチン要件であるため、2022年の市場シェアは試薬・消耗品が過半を占めた。消耗品は、分子診断、免疫測定、病理組織学的検査など、さまざまな診断技術におけるサンプルの前処理、検査、分析に不可欠である。検査とモニタリングの継続的なニーズは、生検手順と血液ベースの検査の普及と相まって、消耗品の持続的な需要を確実なものにしている。一方、医療機器分野は、特に発展途上国における医療インフラの世界的な向上と、先進医療機器へのアクセスの増加により、最も急成長している分野である。革新的な機器は診断精度の向上に貢献し、医療従事者がより早い段階でがんを特定することを可能にする。さらに、診断機器における人工知能(AI)と自動化の統合は、診断プロセスを合理化し、所要時間を短縮し、全体的な効率を高める。

疾患タイプ別:報告書によると、世界の胃がん診断市場は3つの疾患タイプに二分される:腺がん、胃リンパ腫、その他である。腺がんは最も一般的な胃がんのタイプであるため、2022年の市場シェアの大半を占め、最も急成長している。腺癌セグメントの成長は、胃癌の主なタイプとしてその有病率が牽引している。腺がん診断の今後の動向は、リキッドバイオプシーと個別化医療アプローチの統合を含む可能性がある。特定の分子マーカーの同定は標的治療の指針となり、より個別化された治療戦略への移行を強調する。

エンドユーザー別:本レポートによると、世界の胃がん診断市場は、病院、がん専門クリニック、診断ラボ、がん研究機関、その他の5つのエンドユーザーに二分される。病院は胃がん診断の重要な拠点であり、初期スクリーニングから高度な診断手順、その後の治療まで包括的なサービスを提供しているため、2022年の市場シェアは病院が過半数を占めた。専門化された医療チーム、総合的な施設の利用が可能であることが、胃がん診断の主要拠点として病院が選ばれる要因となっている。診断ラボ部門は、ラボベースの診断サービスに対する需要の増加により、最も速いCAGRで成長すると予想される。さらに、分子検査や遺伝子検査の進歩、タイムリーで正確な結果へのニーズ、最先端技術の継続的な統合、自動化、デジタル病理学がこのセグメントの成長に寄与すると予想される。

地域別本レポートでは、北米、アジア太平洋、欧州、中南米、中東・アフリカという地理的事業に基づいて胃がん診断市場を洞察している。北米の胃がん診断市場は2022年に最も高い市場シェアを獲得したが、これは主に胃がんの有病率の高さや人口の高齢化などの理由による。ライフスタイル要因、遺伝的素因、早期発見・診断イニシアチブへの政府の投資、研究開発費の増加やがん研究への政府助成金、早期発見・検診プログラムに対する意識の高まりも成長に寄与している。米国は胃がん診断の世界最強市場であるが、これは同地域が世界的に最も医療支出率の高い地域の一つであるためである。このような医療インフラへの多額の投資が、胃がん診断を含む高度な診断技術の採用を後押ししている。米国政府は病気の発見と診断を改善するためのプログラムに資金を提供している。このことも胃がん診断薬への需要に拍車をかけている。胃がん診断薬は、治療可能な病気の早期診断に使用できる。

アジア太平洋地域の胃がん診断薬市場は、患者人口の増加、医療支出の増加、可処分所得の増加により、急成長が見込まれている。また、予防医療も普及しつつあり、早期発見検査の需要増につながっている。APAC諸国と国際的な製薬企業との協力関係が診断試薬の開発を促進している。政府や民間団体は医療に投資しており、新しい診断施設や技術の開発につながっている。ポイント・オブ・ケア検査は一般的になりつつあり、中国やインドでは胃がんの有病率が高いことから、高度な診断検査への需要が高まっている。

胃がん診断の世界市場ダイナミクス:

成長促進要因:老人人口の増加は胃がん診断市場の成長を後押しする可能性がある。高齢になるほど、がんを発症する可能性は高くなる。米国がん協会によると、がんと診断される人の平均年齢は68歳である。毎年胃がんと診断される10人のうち約6人は65歳以上である。がんは、体内の細胞が傷つくことで発症する。高齢になればなるほど、細胞の損傷が蓄積する時間が長くなり、それが癌につながる可能性がある。これは胃がん診断市場の成長を促進する可能性がある。さらに、経済的に余裕のある個人は、高額な料金を支払う余裕があるため、診断検査を含む予防医療を受ける可能性が高くなるため、可処分所得の増加による市場の成長が期待される。市場成長を牽引するその他の成長要因としては、胃がん有病率の上昇、医療費の増加、早期発見に対する意識の高まりなどが挙げられる。

課題高い診断費用は胃がん診断市場にいくつかの課題をもたらす可能性がある。高度な診断技術には、しばしば多額の金銭的負担が伴う。特に医療予算や医療資源が限られている地域では、このような高額な診断ツールへのアクセスが制限される可能性がある。そのため、診断が遅れたり、不十分であったりする可能性があり、タイムリーな発見に影響を与え、医療格差の一因となる。胃がん診断市場が直面するもう一つの課題は、医療検査専門家の不足である。

トレンド胃がん診断に人工知能(AI)と機械学習を取り入れる傾向が高まっており、画像解析の精度と効率を高め、ルーチン作業を自動化し、リアルタイムの意思決定支援を容易にすることで、この分野を再構築している。これらの技術は、高度なパターン認識、個別化されたリスク予測モデル、継続的な学習を通じて早期発見に貢献し、最終的には診断精度と患者の転帰を改善する。機械学習の適応的な性質により、診断プロセスは新たなトレンドとともに確実に進化し、胃癌診断の状況に変革をもたらす。予測期間中に胃がん診断市場の成長を増大させると考えられるトレンドには、リキッドバイオプシー、技術の進歩などがある。

COVID-19の影響分析と今後の展望:

COVID-19の流行は世界の胃がん診断市場に悪影響を及ぼし、がん検診を含む選択的手術や非必須医療処置の停止につながった。このため、胃がん検診の受診率は低下し、特に若年層の低下が顕著であった。

COVID-19後の胃がん診断市場は、戦略的イニシアティブと公衆衛生キャンペーンにより転換期を迎えている。医療システムは、延期された処置に対処し、タイムリーな発見を保証している。この市場はまた、個々の患者に合わせた治療を行う個別化医療の採用増加や診断技術の進歩にも影響を受けている。人工知能が診断プロセスに組み込まれ、所要時間の短縮と精度の向上が図られている。

競争環境と最近の動向:

世界の胃がん診断市場は断片化されている。世界の胃がん診断市場の主要企業は以下の通り:

バイオ・ラッド・ラボラトリーズ社
MiRXES Pte Ltd
アジレント・テクノロジー
F.ホフマン・ラ・ロシュ社
ヴェラ・ダイアグノスティックス・ホールディング社
マイレイド・ジェネティクス社
アボット
アドバケアファーマ(診断機器)
Qiagen NV.
バイオメリューSA
イルミナ・インク

主要企業は、この市場での競争力を維持するため、新技術の採用、新興市場へのサービス導入など、戦略的な取り組みに絶えず投資している。例えば、2023年11月、アジレント・テクノロジーは、ペムブロリズマブ、化学療法、トラスツズマブ、フルオロピリミジンによる治療に適した胃がんまたはGEJ腺がん患者の同定を支援するPD-L1 IHC 22C3 pharmDx診断薬についてFDAの承認を取得した。このツールは現在6つのがん種で承認されている。


ページTOPに戻る


目次

1. Executive Summary

2. Introduction

2.1 Gastric Cancer Diagnostic: An Overview
2.1.1 Introduction to Gastric Cancer Diagnostic
2.1.2 Ways to Reduce Gastric Cancer Risk

2.2 Gastric Cancer Diagnostic Segmentation: An Overview
2.2.1 Gastric Cancer Diagnostic Segmentation

3. Global Market Analysis

3.1 Global Gastric Cancer Diagnostic Market: An Analysis

3.1.1 Global Gastric Cancer Diagnostic Market: An Overview
3.1.2 Global Gastric Cancer Diagnostic Market by Value
3.1.3 Global Gastric Cancer Diagnostic Market by Product Type (Reagents & Consumables and Instruments)
3.1.4 Global Gastric Cancer Diagnostic Market by Disease Type (Adenocarcinoma, Gastric Lymphoma and Others)
3.1.5 Global Gastric Cancer Diagnostic Market by End User (Hospitals, Diagnostic Labs, Oncology Specialty Clinics, Cancer Research Institutes and Others)
3.1.6 Global Gastric Cancer Diagnostic Market by Region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa)

3.2 Global Gastric Cancer Diagnostic Market: Product Type Analysis

3.2.1 Global Gastric Cancer Diagnostic Market: Product Type Overview
3.2.2 Global Reagents & Consumables Gastric Cancer Diagnostic Market by Value
3.2.3 Global Instruments Gastric Cancer Diagnostic Market by Value

3.3 Global Gastric Cancer Diagnostic Market: Disease Type Analysis

3.3.1 Global Gastric Cancer Diagnostic Market: Disease Type Overview
3.3.2 Global Adenocarcinoma Gastric Cancer Diagnostic Market by Value
3.3.3 Global Lymphoma Gastric Cancer Diagnostic Market by Value
3.3.4 Global Other Gastric Cancer Diagnostic Market by Value

3.4 Global Gastric Cancer Diagnostic Market: End User Analysis

3.4.1 Global Gastric Cancer Diagnostic Market: End User Overview
3.4.2 Global Hospitals Gastric Cancer Diagnostic Market by Value
3.4.3 Global Oncology Specialty Clinics Gastric Cancer Diagnostic Market by Value
3.4.4 Global Diagnostic Labs Gastric Cancer Diagnostic Market by Value
3.4.5 Global Cancer Research Institutes Gastric Cancer Diagnostic Market by Value
3.4.6 Global Others Gastric Cancer Diagnostic Market by Value

4. Regional Market Analysis

4.1 North America Gastric Cancer Diagnostic Market: An Analysis

4.1.1 North America Gastric Cancer Diagnostic Market: An Overview
4.1.2 North America Gastric Cancer Diagnostic Market by Value
4.1.3 North America Gastric Cancer Diagnostic Market by Region (The US, Canada and Mexico)
4.1.4 The US Gastric Cancer Diagnostic Market by Value
4.1.5 Canada Gastric Cancer Diagnostic Market by Value
4.1.6 Mexico Gastric Cancer Diagnostic Market by Value

4.2 Europe Gastric Cancer Diagnostic Market: An Analysis

4.2.1 Europe Gastric Cancer Diagnostic Market: An Overview
4.2.2 Europe Gastric Cancer Diagnostic Market by Value
4.2.3 Europe Gastric Cancer Diagnostic Market by Region (Germany, UK, France, Italy, Spain and Rest of the Europe)
4.2.4 Germany Gastric Cancer Diagnostic Market by Value
4.2.5 UK Gastric Cancer Diagnostic Market by Value
4.2.6 France Gastric Cancer Diagnostic Market by Value
4.2.7 Italy Gastric Cancer Diagnostic Market by Value
4.2.8 Spain Gastric Cancer Diagnostic Market by Value
4.2.9 Rest of Europe Gastric Cancer Diagnostic Market by Value

4.3 Asia Pacific Gastric Cancer Diagnostic Market: An Analysis

4.3.1 Asia Pacific Gastric Cancer Diagnostic Market: An Overview
4.3.2 Asia Pacific Gastric Cancer Diagnostic Market by Value
4.3.3 Asia Pacific Gastric Cancer Diagnostic Market by Region (China, India, South Korea, Japan and Rest of Asia Pacific)
4.3.4 China Gastric Cancer Diagnostic Market by Value
4.3.5 Japan Gastric Cancer Diagnostic Market by Value
4.3.6 India Gastric Cancer Diagnostic Market by Value
4.3.7 South Korea Gastric Cancer Diagnostic Market by Value
4.3.8 Rest of Asia Pacific Gastric Cancer Diagnostic Market by Value

4.4 Latin America Gastric Cancer Diagnostic Market: An Analysis

4.4.1 Latin America Gastric Cancer Diagnostic Market: An Overview
4.4.2 Latin America Gastric Cancer Diagnostic Market by Value

4.5 Middle East and Africa Gastric Cancer Diagnostic Market: An Analysis

4.5.1 Middle East and Africa Gastric Cancer Diagnostic Market: An Overview
4.5.2 Middle East and Africa Gastric Cancer Diagnostic Market by Value

5. Impact of COVID-19

5.1 Impact of COVID-19 on Gastric Cancer Diagnostic Market
5.2 Post COVID-19 Impact on Gastric Cancer Diagnostic Market

6. Market Dynamics

6.1 Growth Drivers
6.1.1 Increase in the Global Geriatric Population
6.1.2 Rising Prevalence of Gastric Cancer
6.1.3 Growing Healthcare Expenditure
6.1.4 Amplified Disposable Income
6.1.5 Rising Awareness about Gastric Cancer

6.2 Challenges
6.2.1 High Diagnostic Cost
6.2.2 Shortage of Medical Laboratory Professionals

6.3 Market Trends
6.3.1 Rise in Adoption of Artificial Intelligence
6.3.2 Liquid Biopsy
6.3.3 Technological Advancements

7. Competitive Landscape

7.1 Global Gastric Cancer Diagnostic Market Players: Financial Comparison

8. Company Profiles

8.1 Agilent Technologies, Inc.
8.1.1 Business Overview
8.1.2 Operating Segments
8.1.3 Business Strategy

8.2 Abbott Laboratories
8.2.1 Business Overview
8.2.2 Operating Segments
8.2.3 Business Strategies

8.3 Qiagen
8.3.1 Business Overview
8.3.2 Operating Regions
8.3.3 Business Strategy

8.4 Bio-Rad Laboratories, Inc.
8.4.1 Business Overview
8.4.2 Operating Segments
8.4.3 Business Strategy

8.5 Roche Holdings AG
8.5.1 Business Overview
8.5.2 Operating Segment
8.5.3 Business Strategy

8.6 BIOMÉRIEUX S.A.
8.6.1 Business Overview
8.6.2 Sales by Application
8.6.3 Business Strategy

8.7 Illumina, Inc.
8.7.1 Business Overview
8.7.2 Operating Revenue
8.7.3 Business Strategy

8.8 Myriad Genetics, Inc.
8.8.1 Business Overview
8.8.2 Business Strategy

8.9 MIRXES PTE. LTD.
8.9.1 Business Overview
8.9.2 Business Strategy

8.10 Vela Diagnostics Pte Ltd
8.10.1 Business Overview
8.10.2 Business Strategy

8.11 Advacare Pharma USA
8.11.1 Business Overview

List of Figures

Figure 1: Ways to Reduce Gastric Cancer Risk
Figure 2: Gastric Cancer Diagnostic Segmentation
Figure 3: Global Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Billion)
Figure 4: Global Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Billion)
Figure 5: Global Gastric Cancer Diagnostic Market by Product Type; 2022 (Percentage, %)
Figure 6: Global Gastric Cancer Diagnostic Market by Disease Type; 2022 (Percentage, %)
Figure 7: Global Gastric Cancer Diagnostic Market by End User; 2022 (Percentage, %)
Figure 8: Global Gastric Cancer Diagnostic Market by Region; 2022 (Percentage, %)
Figure 9: Global Reagents & Consumables Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 10: Global Reagents & Consumables Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Billion)
Figure 11: Global Instruments Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 12: Global Instruments Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 13: Global Adenocarcinoma Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Billion)
Figure 14: Global Adenocarcinoma Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Billion)
Figure 15: Global Lymphoma Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 16: Global Lymphoma Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 17: Global Other Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 18: Global Other Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 19: Global Hospitals Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 20: Global Hospitals Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 21: Global Oncology Specialty Clinics Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 22: Global Oncology Specialty Clinics Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 23: Global Diagnostic Labs Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 24: Global Diagnostic Labs Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 25: Global Cancer Research Institutes Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 26: Global Cancer Research Institutes Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 27: Global Others Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 28: Global Others Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 29: North America Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 30: North America Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 31: North America Gastric Cancer Diagnostic Market by Region; 2022 (Percentage, %)
Figure 32: The US Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 33: The US Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 34: Canada Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 35: Canada Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 36: Mexico Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 37: Mexico Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 38: Europe Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 39: Europe Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 40: Europe Gastric Cancer Diagnostic Market by Region; 2022 (Percentage, %)
Figure 41: Germany Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 42: Germany Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 43: UK Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 44: UK Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 45: France Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 46: France Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 47: Italy Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 48: Italy Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 49: Spain Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 50: Spain Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 51: Rest of Europe Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 52: Rest of Europe Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Billion)
Figure 53: Asia Pacific Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 54: Asia Pacific Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 55: Asia Pacific Gastric Cancer Diagnostic Market by Region; 2022 (Percentage, %)
Figure 56: China Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 57: China Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 58: Japan Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 59: Japan Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 60: India Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 61: India Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 62: South Korea Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 63: South Korea Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 64: Rest of Asia Pacific Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 65: Rest of Asia Pacific Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Billion)
Figure 66: Latin America Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 67: Latin America Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 68: Middle East and Africa Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 69: Middle East and Africa Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 70: Global Percentage of Population Aged 65 Years Or Over; 2022, 2030 & 2050 (Percentage, %)
Figure 71: The US Number of New Stomach Cancer; 2018-2023 (Case Count)
Figure 72: The US Health Consumption Expenditure as a Percentage of GDP; 2016-2022 (Percentage, %)
Figure 73: Global GNI per Capita; 2016-2022 (US$ Thousand)
Figure 74: Global Artificial Intelligence (AI) in Healthcare Market; 2021-2030 (US$ Billion)
Figure 75: Agilent Technologies, Inc. Revenue by Segments; 2022 (Percentage, %)
Figure 76: Abbott Laboratories Sales by Segments; 2022 (Percentage, %)
Figure 77: Qiagen Net Sales by Regions; 2022 (Percentage, %)
Figure 78: Bio-Rad Laboratories, Inc. Net Sales by Segments; 2022 (Percentage, %)
Figure 79: Roche Holdings AG Sales by Operating Segment; 2022 (Percentage, %)
Figure 80: BIOMÉRIEUX S.A. Sales by Application; 2022 (Percentage, %)
Figure 81: Illumina Revenue by Segments; 2022(Percentage, %)
Table 1: Global Gastric Cancer Diagnostic Market Players: Financial Comparison

 

ページTOPに戻る


 

Summary

Gastric cancer diagnostic involves a comprehensive process of identifying stomach cancer through clinical evaluation, imaging studies like endoscopy and CT scans, biopsy for tissue examination, and blood tests to detect specific markers. One of the primary objectives driving growth in gastric cancer diagnostics is the emphasis on early detection. Early-stage identification allows for timely intervention and treatment, significantly improving prognosis and treatment outcomes. The global gastric cancer diagnostic market in 2022 stood at US$1.46 billion, and is likely to reach US$2.25 billion by 2028.

One of the prominent factors driving the rise in gastric cancer diagnostic’s demand include escalating incidence of gastric cancer worldwide and growing awareness among people about gastric cancer prevention. The growing emphasis on preventive healthcare and routine screenings, especially among high-risk populations, is driving the market expansion. Additionally, supportive government initiatives, healthcare infrastructure development, a surge in research and development activities contribute to the market's growth by streamlining diagnostic procedures and improving overall efficiency. Furthermore, the gastric cancer diagnostic market is predicted to grow as the senior population grows and innovations such as liquid biopsies, advanced technologies like improved imaging techniques and molecular diagnostics and integration of AI with healthcare become popular. The global gastric cancer diagnostic market value is projected to grow at a CAGR of 7.46%, during the forecast period of 2023-2028.

Market Segmentation Analysis:

By Product Type: According to the report, the global gastric cancer diagnostic market is segmented into two segments based on the product type: Reagents & consumables and Instruments. Reagents & consumables segment acquired majority of share in the market in 2022, as consumables are a routine requirement in gastric cancer diagnostics. They are essential for sample preparation, testing, and analysis in various diagnostic techniques, including molecular diagnostics, immunoassays, and histopathological examinations. The continuous need for testing and monitoring, coupled with the prevalence of biopsy procedures and blood-based tests, ensures a sustained demand for consumables. While, instruments segment is the fastest growing segment due to global rise in healthcare infrastructure, especially in developing nations and the increasing accessibility to advanced medical equipment. Innovative instruments contribute to improved diagnostic accuracy, enabling healthcare professionals to identify cancer at earlier stages. Moreover, the integration of artificial intelligence (AI) and automation in diagnostic instruments streamlines the diagnostic process, reducing turnaround times and increasing overall efficiency.

By Disease Type: According to the report, the global gastric cancer diagnostic market is bifurcated into three disease types: Adenocarcinoma, Gastric Lymphoma and Others. Adenocarcinoma segment acquired majority of share in the market in 2022 and is the fastest growing segment as well, as this the most common type of stomach cancer. The growth of the Adenocarcinoma segment is driven by its prevalence as the predominant type of gastric cancer. Future trends in Adenocarcinoma diagnostics may involve the integration of liquid biopsy and personalized medicine approaches. The identification of specific molecular markers may guide targeted therapies, emphasizing a move towards more individualized treatment strategies.

By End User: According to the report, the global gastric cancer diagnostic market is bifurcated into five end users: hospitals, oncology specialty clinics, diagnostic labs, cancer research institutes and others. Hospitals acquired majority of share in the market in 2022 as hospitals serve as key hubs for gastric cancer diagnostics, offering a comprehensive range of services from initial screenings to advanced diagnostic procedures and subsequent treatment. Specialized medical teams, and the availability of comprehensive facilities contribute to the increasing preference for hospitals as primary centers for gastric cancer diagnostics. Diagnostic Labs segment is expected to grow at the fastest CAGR, due to the increasing demand for laboratory-based diagnostic services. Furthermore, advances in molecular and genetic testing, along with the need for timely and accurate results, the continued integration of cutting-edge technologies, automation, and digital pathology are expected to contribute to the growth of this segment.

By Region: The report provides insight into the gastric cancer diagnostic market based on the geographical operations, namely North America, Asia Pacific, Europe, Latin America and Middle East and Africa. North America gastric cancer diagnostic market enjoyed the highest market share in 2022, primarily owing to reasons such as the high prevalence of gastric cancer and aging population. Lifestyle factors, genetic predispositions, Governments investments in early detection and diagnosis initiatives, while rising R&D spending and government funding for cancer research, increased awareness of early detection and screening programs also contribute to the growth. The US is the world’s strongest market for gastric cancer diagnostic because the region has one of the highest healthcare spending rates globally. This substantial investment in healthcare infrastructure has driven the adoption of advanced diagnostic technologies, including gastric cancer diagnosis. The US government is funding programs to improve disease detection and diagnosis. This is also fueling demand for gastric cancer diagnostics, which can be used to diagnose diseases early on, when they are more curable.

The Asia Pacific gastric cancer diagnostic market is expected to experience fastest growth due to increasing patient population, rising healthcare spending, and increased disposable income. Preventive healthcare is also gaining popularity, leading to increased demand for early detection tests. Collaborations between APAC countries and international pharmaceutical companies have facilitated the development of diagnostic reagents. Governments and private organizations are investing in healthcare, leading to the development of new diagnostic facilities and technologies. Point-of-care testing is becoming more common, and the high prevalence of gastric cancer in China and India is driving demand for advanced diagnostic tests.

Global Gastric Cancer Diagnostic Market Dynamics:

Growth Drivers: Rising geriatric population has the potential to boost the growth of the gastric cancer diagnostic market. The older a person is, the more likely he is to develop cancer. According to American Cancer Society, the average age of people when they are diagnosed is 68. About 6 of every 10 people diagnosed with stomach cancer each year are 65 or older. Cancer starts when cells in the body get damaged. The older a person gets, the more time there is for cell damage to build up, which can lead to cancer. This can drive the growth of the gastric cancer diagnostics market. Further, the market is expected to grow due to rising disposable income as individuals with larger financial means are more likely to seek preventive medical care, including diagnostic tests, since they can afford the high charges. Other growth drivers driving the market growth includes rising prevalence of gastric cancer, growing healthcare expenditure, rising awareness about early detection, etc.

Challenges: High diagnostic cost can present several challenges for the gastric cancer diagnostic market. Advanced diagnostic technologies often come with substantial financial implications. This high cost can limit accessibility to these diagnostic tools, particularly in regions with limited healthcare budgets and resources. This can lead to delayed or inadequate diagnostic procedures, impacting timely detection and contributing to healthcare disparities. Another challenge that gastric cancer diagnostic market faces is shortage of medical laboratory professionals.

Trends: The rising trend of incorporating Artificial Intelligence (AI) and machine learning in gastric cancer diagnostics is reshaping the field by enhancing precision and efficiency in imaging analysis, automating routine tasks, and facilitating real-time decision support. These technologies contribute to early detection through advanced pattern recognition, personalized risk prediction models, and continuous learning, ultimately improving diagnostic accuracy and patient outcomes. The adaptive nature of machine learning ensures that diagnostic processes evolve with emerging trends, marking a transformative shift in the gastric cancer diagnostic landscape. More trends are believed to augment the growth of gastric cancer diagnostic market during the forecasted period include, liquid biopsies, technological advancements, etc.

Impact Analysis of COVID-19 and Way Forward:

The COVID-19 pandemic has had negative impact on the global gastric cancer diagnostic market, leading to the suspension of elective surgeries and non-essential medical procedures, including cancer screening. This led to a decline in gastric cancer screening rates, with younger adults experiencing the most significant reductions, possibly due to their lower risk of developing the disease.

Post-COVID-19, the gastric cancer diagnostic market is undergoing a transition due to strategic initiatives and public health campaigns. Healthcare systems are addressing deferred procedures and ensuring timely detection. The market is also influenced by increased adoption of personalized medicine, which tailors’ treatment to individual patients, and advancements in diagnostic technologies. Artificial intelligence is being integrated into diagnostic processes, reducing turnaround times and improving accuracy.

Competitive Landscape and Recent Developments:

Global Gastric cancer diagnostic market is fragmented. Key players of global Gastric cancer diagnostic market are:

Bio-Rad Laboratories Inc
MiRXES Pte Ltd
Agilent Technologies Inc
F. Hoffmann-La Roche Ltd
Vela Diagnostics Holding Pte Ltd
Myraid Genetics Inc.
Abbott
AdvaCare Pharma (diagnosis devices)
Qiagen NV.
bioMerieux SA
Illumina Inc

The key players are constantly investing in strategic initiatives, such as adoption of new technologies, introducing their services to emerging markets and more, to maintain a competitive edge in this market. For instance, in November 2023, Agilent Technologies has been approved by the FDA for the PD-L1 IHC 22C3 pharmDx diagnostic, which helps identify patients with gastric or GEJ adenocarcinoma suitable for treatment with pembrolizumab, chemotherapy, trastuzumab, and fluoropyrimidine. The tool is now approved in six cancer types.



ページTOPに戻る


Table of Contents

1. Executive Summary

2. Introduction

2.1 Gastric Cancer Diagnostic: An Overview
2.1.1 Introduction to Gastric Cancer Diagnostic
2.1.2 Ways to Reduce Gastric Cancer Risk

2.2 Gastric Cancer Diagnostic Segmentation: An Overview
2.2.1 Gastric Cancer Diagnostic Segmentation

3. Global Market Analysis

3.1 Global Gastric Cancer Diagnostic Market: An Analysis

3.1.1 Global Gastric Cancer Diagnostic Market: An Overview
3.1.2 Global Gastric Cancer Diagnostic Market by Value
3.1.3 Global Gastric Cancer Diagnostic Market by Product Type (Reagents & Consumables and Instruments)
3.1.4 Global Gastric Cancer Diagnostic Market by Disease Type (Adenocarcinoma, Gastric Lymphoma and Others)
3.1.5 Global Gastric Cancer Diagnostic Market by End User (Hospitals, Diagnostic Labs, Oncology Specialty Clinics, Cancer Research Institutes and Others)
3.1.6 Global Gastric Cancer Diagnostic Market by Region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa)

3.2 Global Gastric Cancer Diagnostic Market: Product Type Analysis

3.2.1 Global Gastric Cancer Diagnostic Market: Product Type Overview
3.2.2 Global Reagents & Consumables Gastric Cancer Diagnostic Market by Value
3.2.3 Global Instruments Gastric Cancer Diagnostic Market by Value

3.3 Global Gastric Cancer Diagnostic Market: Disease Type Analysis

3.3.1 Global Gastric Cancer Diagnostic Market: Disease Type Overview
3.3.2 Global Adenocarcinoma Gastric Cancer Diagnostic Market by Value
3.3.3 Global Lymphoma Gastric Cancer Diagnostic Market by Value
3.3.4 Global Other Gastric Cancer Diagnostic Market by Value

3.4 Global Gastric Cancer Diagnostic Market: End User Analysis

3.4.1 Global Gastric Cancer Diagnostic Market: End User Overview
3.4.2 Global Hospitals Gastric Cancer Diagnostic Market by Value
3.4.3 Global Oncology Specialty Clinics Gastric Cancer Diagnostic Market by Value
3.4.4 Global Diagnostic Labs Gastric Cancer Diagnostic Market by Value
3.4.5 Global Cancer Research Institutes Gastric Cancer Diagnostic Market by Value
3.4.6 Global Others Gastric Cancer Diagnostic Market by Value

4. Regional Market Analysis

4.1 North America Gastric Cancer Diagnostic Market: An Analysis

4.1.1 North America Gastric Cancer Diagnostic Market: An Overview
4.1.2 North America Gastric Cancer Diagnostic Market by Value
4.1.3 North America Gastric Cancer Diagnostic Market by Region (The US, Canada and Mexico)
4.1.4 The US Gastric Cancer Diagnostic Market by Value
4.1.5 Canada Gastric Cancer Diagnostic Market by Value
4.1.6 Mexico Gastric Cancer Diagnostic Market by Value

4.2 Europe Gastric Cancer Diagnostic Market: An Analysis

4.2.1 Europe Gastric Cancer Diagnostic Market: An Overview
4.2.2 Europe Gastric Cancer Diagnostic Market by Value
4.2.3 Europe Gastric Cancer Diagnostic Market by Region (Germany, UK, France, Italy, Spain and Rest of the Europe)
4.2.4 Germany Gastric Cancer Diagnostic Market by Value
4.2.5 UK Gastric Cancer Diagnostic Market by Value
4.2.6 France Gastric Cancer Diagnostic Market by Value
4.2.7 Italy Gastric Cancer Diagnostic Market by Value
4.2.8 Spain Gastric Cancer Diagnostic Market by Value
4.2.9 Rest of Europe Gastric Cancer Diagnostic Market by Value

4.3 Asia Pacific Gastric Cancer Diagnostic Market: An Analysis

4.3.1 Asia Pacific Gastric Cancer Diagnostic Market: An Overview
4.3.2 Asia Pacific Gastric Cancer Diagnostic Market by Value
4.3.3 Asia Pacific Gastric Cancer Diagnostic Market by Region (China, India, South Korea, Japan and Rest of Asia Pacific)
4.3.4 China Gastric Cancer Diagnostic Market by Value
4.3.5 Japan Gastric Cancer Diagnostic Market by Value
4.3.6 India Gastric Cancer Diagnostic Market by Value
4.3.7 South Korea Gastric Cancer Diagnostic Market by Value
4.3.8 Rest of Asia Pacific Gastric Cancer Diagnostic Market by Value

4.4 Latin America Gastric Cancer Diagnostic Market: An Analysis

4.4.1 Latin America Gastric Cancer Diagnostic Market: An Overview
4.4.2 Latin America Gastric Cancer Diagnostic Market by Value

4.5 Middle East and Africa Gastric Cancer Diagnostic Market: An Analysis

4.5.1 Middle East and Africa Gastric Cancer Diagnostic Market: An Overview
4.5.2 Middle East and Africa Gastric Cancer Diagnostic Market by Value

5. Impact of COVID-19

5.1 Impact of COVID-19 on Gastric Cancer Diagnostic Market
5.2 Post COVID-19 Impact on Gastric Cancer Diagnostic Market

6. Market Dynamics

6.1 Growth Drivers
6.1.1 Increase in the Global Geriatric Population
6.1.2 Rising Prevalence of Gastric Cancer
6.1.3 Growing Healthcare Expenditure
6.1.4 Amplified Disposable Income
6.1.5 Rising Awareness about Gastric Cancer

6.2 Challenges
6.2.1 High Diagnostic Cost
6.2.2 Shortage of Medical Laboratory Professionals

6.3 Market Trends
6.3.1 Rise in Adoption of Artificial Intelligence
6.3.2 Liquid Biopsy
6.3.3 Technological Advancements

7. Competitive Landscape

7.1 Global Gastric Cancer Diagnostic Market Players: Financial Comparison

8. Company Profiles

8.1 Agilent Technologies, Inc.
8.1.1 Business Overview
8.1.2 Operating Segments
8.1.3 Business Strategy

8.2 Abbott Laboratories
8.2.1 Business Overview
8.2.2 Operating Segments
8.2.3 Business Strategies

8.3 Qiagen
8.3.1 Business Overview
8.3.2 Operating Regions
8.3.3 Business Strategy

8.4 Bio-Rad Laboratories, Inc.
8.4.1 Business Overview
8.4.2 Operating Segments
8.4.3 Business Strategy

8.5 Roche Holdings AG
8.5.1 Business Overview
8.5.2 Operating Segment
8.5.3 Business Strategy

8.6 BIOMÉRIEUX S.A.
8.6.1 Business Overview
8.6.2 Sales by Application
8.6.3 Business Strategy

8.7 Illumina, Inc.
8.7.1 Business Overview
8.7.2 Operating Revenue
8.7.3 Business Strategy

8.8 Myriad Genetics, Inc.
8.8.1 Business Overview
8.8.2 Business Strategy

8.9 MIRXES PTE. LTD.
8.9.1 Business Overview
8.9.2 Business Strategy

8.10 Vela Diagnostics Pte Ltd
8.10.1 Business Overview
8.10.2 Business Strategy

8.11 Advacare Pharma USA
8.11.1 Business Overview

List of Figures

Figure 1: Ways to Reduce Gastric Cancer Risk
Figure 2: Gastric Cancer Diagnostic Segmentation
Figure 3: Global Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Billion)
Figure 4: Global Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Billion)
Figure 5: Global Gastric Cancer Diagnostic Market by Product Type; 2022 (Percentage, %)
Figure 6: Global Gastric Cancer Diagnostic Market by Disease Type; 2022 (Percentage, %)
Figure 7: Global Gastric Cancer Diagnostic Market by End User; 2022 (Percentage, %)
Figure 8: Global Gastric Cancer Diagnostic Market by Region; 2022 (Percentage, %)
Figure 9: Global Reagents & Consumables Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 10: Global Reagents & Consumables Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Billion)
Figure 11: Global Instruments Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 12: Global Instruments Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 13: Global Adenocarcinoma Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Billion)
Figure 14: Global Adenocarcinoma Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Billion)
Figure 15: Global Lymphoma Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 16: Global Lymphoma Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 17: Global Other Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 18: Global Other Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 19: Global Hospitals Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 20: Global Hospitals Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 21: Global Oncology Specialty Clinics Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 22: Global Oncology Specialty Clinics Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 23: Global Diagnostic Labs Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 24: Global Diagnostic Labs Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 25: Global Cancer Research Institutes Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 26: Global Cancer Research Institutes Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 27: Global Others Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 28: Global Others Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 29: North America Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 30: North America Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 31: North America Gastric Cancer Diagnostic Market by Region; 2022 (Percentage, %)
Figure 32: The US Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 33: The US Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 34: Canada Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 35: Canada Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 36: Mexico Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 37: Mexico Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 38: Europe Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 39: Europe Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 40: Europe Gastric Cancer Diagnostic Market by Region; 2022 (Percentage, %)
Figure 41: Germany Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 42: Germany Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 43: UK Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 44: UK Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 45: France Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 46: France Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 47: Italy Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 48: Italy Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 49: Spain Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 50: Spain Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 51: Rest of Europe Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 52: Rest of Europe Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Billion)
Figure 53: Asia Pacific Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 54: Asia Pacific Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 55: Asia Pacific Gastric Cancer Diagnostic Market by Region; 2022 (Percentage, %)
Figure 56: China Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 57: China Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 58: Japan Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 59: Japan Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 60: India Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 61: India Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 62: South Korea Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 63: South Korea Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 64: Rest of Asia Pacific Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 65: Rest of Asia Pacific Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Billion)
Figure 66: Latin America Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 67: Latin America Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 68: Middle East and Africa Gastric Cancer Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 69: Middle East and Africa Gastric Cancer Diagnostic Market by Value; 2023-2028 (US$ Million)
Figure 70: Global Percentage of Population Aged 65 Years Or Over; 2022, 2030 & 2050 (Percentage, %)
Figure 71: The US Number of New Stomach Cancer; 2018-2023 (Case Count)
Figure 72: The US Health Consumption Expenditure as a Percentage of GDP; 2016-2022 (Percentage, %)
Figure 73: Global GNI per Capita; 2016-2022 (US$ Thousand)
Figure 74: Global Artificial Intelligence (AI) in Healthcare Market; 2021-2030 (US$ Billion)
Figure 75: Agilent Technologies, Inc. Revenue by Segments; 2022 (Percentage, %)
Figure 76: Abbott Laboratories Sales by Segments; 2022 (Percentage, %)
Figure 77: Qiagen Net Sales by Regions; 2022 (Percentage, %)
Figure 78: Bio-Rad Laboratories, Inc. Net Sales by Segments; 2022 (Percentage, %)
Figure 79: Roche Holdings AG Sales by Operating Segment; 2022 (Percentage, %)
Figure 80: BIOMÉRIEUX S.A. Sales by Application; 2022 (Percentage, %)
Figure 81: Illumina Revenue by Segments; 2022(Percentage, %)
Table 1: Global Gastric Cancer Diagnostic Market Players: Financial Comparison

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(バイオ薬物)の最新刊レポート

Daedal Research 社の最新刊レポート

本レポートと同じKEY WORD(oncology)の最新刊レポート


よくあるご質問


Daedal Research社はどのような調査会社ですか?


デダルリサーチ (Daedal Research) はインドとアジアを始めとして世界の医療や医薬、ICT、エネルギー、通信、化学、交通、消費財などの様々な市場を調査対象とした市場調査報告書を出版してい... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/07 10:27

155.63 円

167.26 円

203.27 円

ページTOPに戻る